Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
20.61
+0.53 (2.64%)
Dec 20, 2024, 4:00 PM EST - Market closed
Instil Bio Employees
Instil Bio had 49 employees as of December 31, 2023. The number of employees decreased by 143 or -74.48% compared to the previous year.
Employees
49
Change (1Y)
-143
Growth (1Y)
-74.48%
Revenue / Employee
n/a
Profits / Employee
-$1,533,980
Market Cap
134.50M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 49 | -143 | -74.48% |
| Dec 31, 2022 | 192 | -220 | -53.40% |
| Dec 31, 2021 | 412 | 262 | 174.67% |
| Dec 31, 2020 | 150 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Jin Medical International | 245 |
| Puma Biotechnology | 185 |
| Seer, Inc. | 147 |
| Enanta Pharmaceuticals | 145 |
| Tenaya Therapeutics | 140 |
| Compugen | 68 |
| InflaRx | 62 |
| Monopar Therapeutics | 10 |
TIL News
- 20 days ago - Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity - Seeking Alpha
- 3 months ago - Crude Oil Surges Over 1%; Instil Bio Shares Plunge - Benzinga
- 3 months ago - Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer - GlobeNewsWire
- 3 months ago - Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements - Seeking Alpha
- 4 months ago - Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody - GlobeNewsWire
- 8 months ago - Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire